User:WikiLinuz/Psychoactive substances/ADHD psychostimulants

< User:WikiLinuz‎ | Psychoactive substances

Clinical ADHD stimulants

Zhang L, Honghui Y, Lin L, Ebba R, Pontus A, Miguel A, Brian D, Samuele C, Henrik L, Chang Z (23 November 2022). "Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis". JAMA. 5 (11). doi:10.1001/jamanetworkopen.2022.43597.
Jason Y (January 2011). "The Dopamine Dilemma: Long-term efficacy of stimulant use in ADHD". Innovations in Clinical Neuroscience. 8 (1). PMID 21311708.
Kinda I, Parastou D (24 September 2014). "Drug Holidays From ADHD Medication: International Experience Over the Past Four Decades". Journal of Attention Disorders. 19 (7). doi:10.1177/1087054714548035.
Joshua T (18 November 2021). "Prescription Stimulant-Induced Neurotoxicity: Mechanisms, outcomes, and relevance to ADHD". University of Michigan School of Public Health.
Anupom B, Kochupurackal M. "Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents". Journal of Pineal Research. doi:10.1111/j.1600-079X.2009.00713.x. PMID 19796048.
Gonzalo T, Raul G, Marc C (January 2003). "Plasma membrane monoamine transporters: structure, regulation and function". Nature.

Retrieved from "https://en.wikipedia.org/w/index.php?title=User:WikiLinuz/Psychoactive_substances/ADHD_psychostimulants&oldid=1155305960"